| Autor: |
Zakalashvili M; 1Hepatology and Gastroenterology Department, Medical Center Mrcheveli, Tbilisi; 3University of Georgia, Tbilisi, Georgia., Butsashvili M; 2Health Research Union/Clinic NEOLAB, Tbilisi; 3University of Georgia, Tbilisi, Georgia., Zarkua J; 1Hepatology and Gastroenterology Department, Medical Center Mrcheveli, Tbilisi; 3University of Georgia, Tbilisi, Georgia., Abzianidze T; 2Health Research Union/Clinic NEOLAB, Tbilisi; 3University of Georgia, Tbilisi, Georgia., Kamkamidze G; 2Health Research Union/Clinic NEOLAB, Tbilisi; 3University of Georgia, Tbilisi, Georgia., Metreveli D; 1Hepatology and Gastroenterology Department, Medical Center Mrcheveli, Tbilisi; Georgia. |
| Abstrakt: |
Hepatitis B virus infection remains one of the major healthcare problems in Georgia with an exposure prevalence of 25.9% (Positive Anti-HBc) and chronic HBV infection (Positive HBsAg) 2.9%. Determination of clinical phase of chronic HBV infection is crucial for evaluation prognosis and accordingly, initiation of antiviral treatment, which might be lifelong. The specific aim of our study was to collect data on clinical characteristics of HBV-infected patients and determine the clinical phases of chronic HBV infection in the Georgian population. We randomly selected 111 chronic HBV-infected patients from the database of the medical center Mrcheveli. Liver fibrosis was assessed by Fibroscan, and viral load data were computed by the Real Time polymerase chain reaction (PCR) methodology. Liver fibrosis results were available for 74 of the patients (67%), and a majority of patients (72 of the 74, 97%) had no signs of advanced liver fibrosis. Viral load data were available for 94 patients, of whom 70 (74.5%) had an HBV-DNA level less than 2000 IU/ml, while 18 (19.1%) had an HBV-DNA level between 2000 and 20000 IU/ml and 6 (6.4%) were higher than 20000 IU/ml. Data for the assessment of the clinical phase of chronic HBV infection were available for 54% of patients (60 of the 111). Only 3.3% (2/60) of patients had undetectable HBV-DNA and 75% (45/60) had a viral load <2000 IU/ml. Two patients were HBeAg-positive, one of them with hepatitis and another with normal ALT. A few patients classified as HBeAg-negative with chronic hepatitis given normal ALT criteria: 3/60 (5%) by EASL and 6/50 (10%) patients by AASLD. In summary, 11/60 (18.5%) and 8/60 (13.5%) patients had HBV-DNA >2000 IU/ml but a normal ALT. Given the small number of patients, we cautiously conclude that most patients (75%) had HBeAg-positive or -negative chronic HBV infection without hepatitis. However, up to 19% of patients were not possible to classify in any of the internationally recognized phases of HBV infection. Patients within this indeterminate grey area, should be evaluated cautiously and management needs to be individualized. It will be interesting to evaluate the reason high viral load in HBeAg negative patients with normal ALT and long-term outcome among these patients (liver fibroses and/or HCC development). |
